Sipuleucel-T for therapy of asymptomatic or minimally symptomatic, castrate-refractory prostate cancer: an update and perspective among other treatments.

Content Provider	Europe PMC
Author	Gupta, Shilpa Carballido, Estrella Fishman, Mayer
Copyright Year	2011
Abstract	Sipuleucel-T is an autologous cell immunotherapy for castrate-refractory prostate cancer, with US Food and Drug Administration (FDA) approval in asymptomatic or minimally symptomatic prostate cancer. In this review we address the background of prostate cancer incidence and other available therapy onto which sipuleucel-T treatment has been added, with discussion of hormone-therapy, chemotherapy, and other investigational immunotherapies. The sipuleucel-T manufacturing process, toxicity and clinical benefit are reviewed, along with an examination of the issue of clinical benefit to survival, independent of apparent changes of prostate-specific antigen (PSA) levels. Sipuleucel-T therapy is appraised from clinician, patient and immunotherapeutic perspectives, with reference to the clinical data from the pivotal trial, the mechanism of action, and the treatment process.
Journal	Oncotargets and Therapy
Volume Number	4
PubMed Central reference number	PMC3143908
PubMed reference number	21792315
e-ISSN	11786930
DOI	10.2147/ott.s14107
Language	English
Publisher	Dove Medical Press
Publisher Date	2011-06-29
Access Restriction	Open
Rights License	This is an Open Access article which permits unrestricted noncommercial use, provided the original work is properly cited. © 2011 Gupta et al, publisher and licensee Dove Medical Press Ltd.
Subject Keyword	sipuleucel-T immunotherapy vaccine dendritic cells
Content Type	Text
Resource Type	Article
Subject	Pharmacology (medical) Oncology